Transcription factor NF-kappaB inhibitors as single therapeutics agents or in combination with classical chemotherapeutic agents for the treatment of hematologic malignancies

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023736%3A_____%2F10%3A00008797" target="_blank" >RIV/00023736:_____/10:00008797 - isvavai.cz</a>

Result on the web

—

DOI - Digital Object Identifier

—

Result language

angličtina

Original language name

Transcription factor NF-kappaB inhibitors as single therapeutics agents or in combination with classical chemotherapeutic agents for the treatment of hematologic malignancies

Original language description

Nuclear factor-kappaB (NF-kappaB) upregulates the transcription of proteins that promote cell survival, stimulate growth, induce angiogenesis and reduce susceptibility to apoptosis. NF-kappaB signaling pathway is constitutively activated in myelodysplastic syndrome (MDS), acute myeloid leukemia, acute lymphocytic leukemia, chronic myeloid leukemia, chronic lymphocytic leukemia, lymphomas and in multiple myeloma (MM). The overexpression of NF-kappaB and its anti-apoptotic cytoprotective effect suggest that it might be a useful therapeutic target for the treatment of hematologic malignancies. Several drugs effective for the treatment of MM, including proteasome inhibitors, thalidomide, lenalidomide and arsenic trioxide, block NF-kappaB activation. New agents with NF-kappaB inhibitory ativity enhance the anti-MM effects of conventional chemotherapeutic agents and reduce different side-effects. These agents are also studied in the therapy of other hematologic malignancies.

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FD - Oncology and haematology

OECD FORD branch

—

Project

<a href="/en/project/LC06044" target="_blank" >LC06044: Center for Experimental Hematology</a><br>

Continuities

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>Z - Vyzkumny zamer (s odkazem do CEZ)

Publication year

2010

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Current Molecular Pharmacology

ISSN

1874-4672

e-ISSN

—

Volume of the periodical

3

Issue of the periodical within the volume

3

Country of publishing house

AE - UNITED ARAB EMIRATES

Number of pages

25

Pages from-to

98-122

UT code for WoS article

—

EID of the result in the Scopus database

—